查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球磁共振成像造影劑市場 - 2023-2030 年
市場調查報告書
商品編碼
1316235

全球磁共振成像造影劑市場 - 2023-2030 年

Global MRI Contrast Media Agents Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

2022 年，全球核磁共振成像造影劑市場規模達到21 億美元，預計到2030 年將實現利潤豐厚的成長，達到35 億美元。在預測期內（2023-2030 年），全球核磁共振成像造影劑市場預計將呈現6.9% 的年複合成長率。

由於核磁共振成像技術的改進，包括高場強核磁共振成像系統、多參數成像和功能性核磁共振成像，核磁共振成像的臨床應用日益增多。由於這些發展，人們現在需要更強效、更專業的造影劑，以提供更好的圖像品質和診斷精度。

市場動態

核磁共振成像造影劑的FSA 批准推動了預測期內全球核磁共振成像造影劑市場的成長

例如，2023 年2 月，Bracco 公司和加柏公司幾乎同時推出了名為钆噴酸醇的全新MRI 造影劑。這兩種造影劑基於相同的分子結構，只需钆的一半劑量就能進行造影劑增強型核磁共振成像掃描，儘管兩家公司都以各自的品牌銷售钆噴酸酯。

美國食品和藥物管理局（FDA）已經批准了一種新型磁共振成像（MRI）造影劑- 钆噴酸諾，它具有良好的弛豫性和較低的钆劑量。

活躍的主要企業為全球磁共振成像造影劑提供了市場成長機會

例如，2023 年4 月，GE HealthCare 宣布推出Pixxoscan（钆布醇），這是一種用於磁共振成像（MRI）的大環、非離子型钆基造影劑（GBCA）。 Pixxoscan 已在奧地利獲得銷售許可，正在等待批准，目前已通過監管分散程序(DCP) 評估，將於2023 年在其他歐洲國家上市。

根據審查結果，Pixxoscan 在品質和數量上與Gadovist 參考產品具有相同的活性成分和輔料成分，以及相同的藥物形式。

COVID-19 影響分析

COVID-19 大流行對核磁共振成像造影劑市場產生了重大影響。疫情改變了資源分配和醫療保健的優先次序。為了支持與COVID-19 相關的病人護理和分流，核磁共振成像掃描儀和造影劑等成像資源被重新分配。用於非COVID-19 的核磁共振成像造影劑的供應和應用可能會受到資源重新分配的影響。

俄烏衝突分析

俄烏戰爭對核磁共振成像造影劑市場的影響是複雜和多方面的。衝突環境可能會阻礙人們使用核磁共振成像掃描儀等尖端醫療設備。如果醫療設施或醫療基礎設施遭到破壞或無法進入，衝突會限制受影響地區使用核磁共振成像造影劑。

目 錄

第1 章：研究方法與範圍

  • 研究方法
  • 報告的研究目標和範圍

第2章：定義和概述

第3章：執行摘要

  • 按產品分類
  • 按類型分類
  • 按適應症分類
  • 按最終用戶分類
  • 按地區分類

第四章：動態

  • 影響因素
    • 促進因素
      • 慢性疾病增加
    • 制約因素
      • 磁共振成像造影劑的不良反應
    • 機會
      • 技術進步
    • 影響分析

第5 章：行業分析

  • 波特五力分析法
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • COVID-19 期間的情景
    • COVID-19 後的情況
  • COVID-19 期間的定價動態
  • 供需關係
  • 大流行期間與市場相關的政府計劃
  • 製造商的戰略計劃
  • 結論

第7 章：俄烏戰爭分析

第8章：人工智慧分析

第9章：按產品分類

  • 順磁劑
  • 超順磁性製劑

第十章：按適應症分類

  • 臨床
  • 臨床前

第11 章：按適應症分類

  • 癌症
  • 胃腸道
  • 肝膽
  • 神經系統成像
  • 其他

第12 章：按最終用戶分類

  • 醫院
  • 成像中心
  • 其他

第13 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第14 章：競爭格局

  • 競爭格局
  • 產品基準
  • 公司佔有率分析
  • 主要發展和戰略

第15 章：公司簡介

  • GE Healthcare
    • 公司概況
    • 產品組合和說明
    • 財務概況
    • 主要發展
  • Bracco Imaging SPA
  • Bayer AG
  • Guerbet
  • Lantheus Medical Imaging
  • Unijules Life Sciences
  • B. Chemicals and Pharmaceuticals Ltd.
  • SANOCHEMIA Pharmazeutika GmbH
  • Taejoon Pharm
  • Jodas Expoim

第16 章：附錄

簡介目錄
Product Code: MI6532

Market Overview

The global MRI contrast media agents market reached US$ 2.1 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 3.5 billion by 2030. The global MRI contrast media agents market is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

The clinical uses of MRI have increased as a result of improvements in MRI technology, including high-field MRI systems, multi-parametric imaging, and functional MRI. Because of these developments, there is now a desire for more potent and specialized contrast media agents that can deliver better image quality and diagnostic precision.

Market Dynamics

FSA Approval For MRI Contrast Media Agents is Boosting the Global MRI Contrast Media Agents Market Growth During the Forecast Period

For instance, in February 2023, the unveiling of a brand-new MRI contrast agent called gadopiclenol that Bracco and Guerbet jointly created took place almost simultaneously. The agents are based on the same molecular structure and offer the possibility of contrast-enhanced MRI scans at half the dose of gadolinium, despite the fact that each business is marketing gadopiclenol under its respective brand names.

The Food and Drug Administration (FDA) has approved gadopiclenol, a novel magnetic resonance imaging (MRI) contrast agent that delivers good relaxivity and a lower gadolinium dose.

Active Key Players Provide Global MRI Contrast Media Agents with Market Growth Opportunities

For instance, in April 2023, GE HealthCare announced the availability of Pixxoscan (gadobutrol), a macrocyclic, non-ionic gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI). With a marketing license in place in Austria and pending approval, Pixxoscan has undergone regulatory decentralized procedure (DCP) evaluation and will be available in other European nations in 2023.

According to a review, it has the same active ingredient and excipient composition in terms of both quality and quantity, as well as the same pharmaceutical form, as the Gadovist reference product.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the MRI contrast media agents market. The epidemic has caused a change in the allocation of resources and healthcare priorities. In order to support patient care and triage linked to COVID-19, imaging resources such as MRI scanners and contrast media agents were reallocated. The availability and application of MRI contrast media agents for non-COVID-19 use may be impacted by this resource reallocation.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the MRI contrast media agents market is complex and multifaceted. Conflict circumstances may prevent people from using cutting-edge medical equipment, such as MRI scanners. Conflict can restrict the use of MRI contrast media agents in impacted areas if medical facilities or healthcare infrastructure are destroyed or inaccessible.

Segment Analysis

The global MRI contrast media agents market is segmented based on type, product, indication, end-user, and region.

The Superparamagnetic Agent Segment is Holding 42.7% market share in the Market in 2022

The superparamagnetic agents segment accounted for approximately 42.7% of the MRI contrast media agents market share in 2022. When exposed to an external magnetic field, superparamagnetic substances can align with it and quickly demagnetize when the field is withdrawn. Superparamagnetic agents do not show any residual magnetization, in contrast to ferromagnetic materials, which do so even in the absence of an external field. The main purpose of superparamagnetic substances is to improve contrast in MRI scans.

These substances aggregate in certain organs or blood vessels of interest when given intravenously, including the liver, spleen, lymph nodes, and blood arteries. They produce a local magnetic field distortion because of their magnetic characteristics, which changes the relaxation durations of adjacent water protons. The structures or regions holding the contrast agent are now easier to discern in the subsequent MRI images as a result of this modification, which results in a change in signal intensity.

Geographical Analysis

Advancements in MRI Contrast Media Agents Dominate the North American Region

North America is expected to dominate the MRI contrast media agents market, accounting for around 39.4% of this market. Modern medical imaging methods, such as MRI, are widely used throughout North America. In several therapeutic specialties, including neurology, cardiology, cancer, and musculoskeletal imaging, MRI scans are frequently employed. The market for MRI contrast media agents is driven by the rising use of MRI scans in North America. The development of medical imaging technology is leading the way in the region.

The region's research and development efforts are concentrated on creating novel contrast media agents with enhanced imaging characteristics, safety profiles, and targeted targeting abilities. The development of MRI contrast media agents is aided by the presence of top pharmaceutical and medical device businesses in the region.

Competitive Landscape

The major global players in the market include: GE Healthcare, Bracco Imaging SPA, Bayer AG, Guerbet, Lantheus Medical Imaging, Unijules Life Sciences, B. Chemicals and Pharmaceuticals Ltd., Sanochemia Pharmazeutika GmbH, Taejoon Pharm, and Jodas Expoim among others.

Why Purchase the Report?

  • To visualize the global MRI contrast media agent's market segmentation based on the product, type, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of MRI contrast media agents market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global MRI contrast media agents market report would provide approximately 69 tables, 66 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Type
  • 3.3. Snippet by Indication
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse reactions to MRI contrast media agents
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Paramagnetic Agents*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Superparamagnetic Agents

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Clinical*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Preclinical

11. By Indication

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Cancer*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Gastrointestinal
  • 11.4. Hepatobiliary
  • 11.5. Neurological Imaging
  • 11.6. Others

12. By End-user

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.1.2. Market Attractiveness Index, By End-user
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Imaging Centers
  • 12.4. Other

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. GE Healthcare*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Bracco Imaging SPA
  • 15.3. Bayer AG
  • 15.4. Guerbet
  • 15.5. Lantheus Medical Imaging
  • 15.6. Unijules Life Sciences
  • 15.7. B. Chemicals and Pharmaceuticals Ltd.
  • 15.8. SANOCHEMIA Pharmazeutika GmbH
  • 15.9. Taejoon Pharm
  • 15.10. Jodas Expoim

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us